Tuberculosis & respiratory diseases · 2016 · 34 citations · 23 references
MedicineCell BiologyPharmacologyBiochemical PharmacologyCellular MetabolismInflammationAntifibrotic TherapyFibrosisInterstitial Lung DiseasePulmonary InflammationFibrotic ChangeFibrotic Interstitial Lung DiseaseInterstitital Lung DiseaseLung Disease ProgressionLung FibrosisOxidoreductase FunctionPulmonary Fibrosis Progression
BACKGROUND: levels on bleomycin-induced lung fibrosis in mice. METHODS: C57BL/6 mice were treated with intratracheal instillation of bleomycin. The mice were orally administered with β-lapachone from 3 days before exposure to bleomycin to 1-3 weeks after exposure to bleomycin. Bronchoalveolar lavage fluid (BALF) was collected for analyzing the infiltration of immune cells. In vitro, A549 cells were treated with transforming growth factor β1 (TGF-β1) and β-lapachone to analyze the extracellular matrix (ECM) and epithelial-mesenchymal transition (EMT). RESULTS: β-Lapachone strongly attenuated bleomycin-induced lung inflammation and fibrosis, characterized by histological staining, infiltrated immune cells in BALF, inflammatory cytokines, fibrotic score, and TGF-β1, α-smooth muscle actin accumulation. In addition, β-lapachone showed a protective role in TGF-β1-induced ECM expression and EMT in A549 cells. CONCLUSION: /NADH ratio through NQO1 activation.
23
Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Luca Richeldi, Roland M. du Bois, Ganesh Raghu et al. · New England Journal of Medicine · 2014 · 4.6K citations · Full text
Pirfenidone in idiopathic pulmonary fibrosis
H. Taniguchi, Masahito Ebina, Yasuhiro Kondoh et al. · European Respiratory Journal · 2009 · 946 citations · Full text